首页
400-620-6333
切换导航
搜索
基本描述
| 产品名称 | ICOS ligand |
|---|
产品规格参数
| CAS编号和信息 | rp174246 |
|---|
关联配体
| Ligand ID | 9593 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 名称 | ICOS ligand | ||||||||||
| 别名 | B7 homolog 2 | ||||||||||
| 类别 | Peptide | ||||||||||
| 学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide | ||||||||||
| 生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
||||||||||
| 评价 |
Endogenous ligand for ICOS that is expressed on the surface of antigen presenting cells. Inhibiting the ICOS/ICOSL axis is predicted to provide anti-inflammatory activity applicable for the treatment of autoimmune diseases. The ICOSL protein contains an immunoglobulin (Ig)-like domain that resembles the antibody variable domain, that has been coined the 'V-set domain'. The genes for all human V-set domain containing proteins are listed in HGNC gene group 590. The anti-ICOSL monoclonal antibody MEDI5872 (AMG557) is being evaluated in Phase 2 clinical trial in patients with primary Sjögren's syndrome (NCT02334306). Phase 1 trials of the same biologic in systemic lupus erythematosus (SLE) and psoriasis were terminated. |
||||||||||
| 配体家族 | CD molecules (ligands) | ||||||||||
| 基因/前体 |
|
||||||||||
| 单字母多肽序列 | MRLGSPGLLFLLFSSLRADTQEKEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFNVTPQDEQKFHCLVLSQSLGFQEVLSVEVTLHVAANFSVPVVSAPHSPSQDELTFTCTSINGYPRPNVYWINKTDNSLLDQALQNDTVFLNMRGLYDVVSVLRIARTPSVNIGCCIENVLLQQNLTVGSQTGNDIGERDKITENPVSTGEKNAATWSILAVLCLLVVVAVAIGWVCRDRCLQHSYAGAWAVSPETELTGHV | ||||||||||
| 三字母多肽序列 | |||||||||||
| 翻译后修饰 |
Signal peptide 1-18 Mature peptide 19-302 Transmembrane region 257-277 |
||||||||||
| 化学修饰 |
产品问答
产品问答
上海阿拉丁生化科技股份有限公司
? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任
危险品化学品经营许可证（带存储）